HHS Press Release: 2015 Medicare Part B premiums and deductibles to remain the same as last two years
U.S. Department of Health & Human Services - October 9, 2014
Premiums, copays and deductibles for other Medicare programs for 2015 also announced.
For 2015, almost 9 out of 10 Medicare Part D plans will have a preferred pharmacy network
Drug Channels - October 14, 2014
Read on for our exclusive look at the 2015 Part D landscape, which includes insights on the major health plans—UnitedHealthcare, Humana, Express Scripts, et al—behind the PDPs.
Reform Update: Generic drugs' high prices spur fears of failed drug adherence
Modern Healthcare - October 9, 2014
Faced with the rising costs of generic prescription drugs, health insurers increasingly are turning to tiers and preferred lists on their formularies to keep costs down.
‘Financial Toxicity:’ Who’s Really to Blame for High Cancer Drug Prices?
Wall Street Journal - October 7, 2014
The issue of expensive cancer drugs is hardly new, of course, but 60 Minutes aired a segment that likely helped highlight the controversy for the mass audience that watches the popular news program. The episode, however, is unlikely to have helped the pharmaceutical industry.
Giant Step Toward New Diabetes Treatment
Harvard University - October 9, 2014
Harvard stem cell researchers announced that they have made a giant leap forward in the quest to find a truly effective treatment for Type 1 Diabetes, a condition that affects an estimated 3 million Americans at a cost of about $15 billion annually.
Higher deductibles squeezing workers
Wire Reports - October 11, 2014
Premiums steady, but out-of-pocket costs rise - When workers across the country crack open their annual employee benefits packages this fall, many are likely to feel immediate relief. Premiums for their employer-provided health insurance will be up, but not as much as in the past.
Health Law Drug Plans Are Given a Check-Up
New York Times - October 7, 2014
When the new health insurance exchanges opened for business one year ago, whether they would succeed was a matter of fervent debate.
The rise of specialty drugs and healthcare costs: 6 things to know
Becker's Hospital Review - October 07, 2014
The pharmaceutical industry's recent shift in focus from "small molecule" medications to specialty drugs — such as Gilead Sciences' hepatitis C drug Sovaldi — will likely have a significant effect on overall healthcare costs during the next decade, according to a Health Affairs study conducted by Duke University researchers.
If you want an antibiotic see your doctor later in the day
Medical Xpress - October 6, 2014
Clinicians make many patient care decisions each day, and the cumulative demand of these decisions may make inappropriate choices more likely later in the day.
Attacking type 2 diabetes from a new direction with encouraging results
Rutgers University - October 5, 2014
Type 2 diabetes affects an estimated 28 million Americans according to the American Diabetes Association, but medications now available only treat symptoms, not the root cause of the disease.
Novel Bacterial Genome Roadmap Opens Drug Discovery Pathway
Genetic Engineering & Biotechnology News - October 7, 2014
Scientists at the University of Illinois at Urbana-Champaign and Northwestern University say they have demonstrated the value of an algorithm to analyze microbial genomic data and speed discovery of new therapeutic drugs.
Many On Medicaid See Boost In Benefits As Economy Improves
Kaiser Health News - October 14, 2014
With an improving fiscal climate, many states are increasing benefits for Medicaid recipients and paying their providers more.
Contact,
Jan Tankersley
Senior Vice President, Marketing & Sales
Pharmaceutical Strategies Group (PSG)
Office: 972-943-7141
Email: JTankersley@PSGConsults.com
PSGNewsletter@PSGConsults.com
www.PSGConsults.com
 |
 |
 |